EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation

Mokhtar Rejili, Md Sadique Hussain, Faouzi Haouala, Yumna Khan, Mudasir Maqbool, Gaurav Gupta

Bioorganic Chemistry · 2025

DOI: 10.1016/j.bioorg.2025.109097 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Mokhtar Rejili und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Sciences, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 146 Literaturangaben. Gefördert von: Imam Mohammed Ibn Saud Islamic University, Imam Mohammed Ibn Saud Islamic University Deanship of Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is a significant clinical problem with late diagnosis, high recurrence, and resistance to therapy. Greater reliance on ubiquitin to induce the degradation of oncogenic proteins instead of inhibiting their activity is provided by proteolysis-targeting chimeras (PROTACs). This review outlines the molecular architecture of PROTACs, their use against important ovarian cancer-driven molecular targets, including BRD4, NAMPT, FAK, FER, and TG2, and the benefits over traditional inhibitors, which include enhanced selectivity, longer efficacy, and ability to target undruggable targets. We also talk about the key obstacles to clinical translation, such as off-target effects, unfavorable pharmacokinetics, and tumor microenvironment concerns, and emerging technologies, including nanoparticle delivery and light-responsive or reversible PROTACs. As PROTACs progress from preclinical research to clinical implementation, their incorporation into ovarian cancer treatment presents a new model for precision oncology. This review highlights the therapeutic potential of PROTACs by linking preclinical progress to translational options to expand precision oncology to treat ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsHumansFemaleProteolysisBiological AvailabilityAnimalsMolecular StructureProteolysis Targeting Chimera

Stichwörter der Autor:innen

Antineoplastic agentsDrug resistanceE3 ubiquitin ligasesMolecular targeted therapyProtein degradationUbiquitin-proteasome system

Substanzen

Antineoplastic AgentsProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Biology, College of Sciences, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia.
  • Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand 248007, India. Electronic address: sadiquehussain007@gmail.com.
  • Institute of Biotechnology and Genetic Engineering (Health Division), The University of Agriculture, Peshawar 25000, Khyber Pakhtunkhwa, Pakistan.
  • Department of Pharmacology, Government Medical College Baramulla, Jammu and Kashmir 193103, India.
  • Centre for Research Impact & Outcome-Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emir…

Förderung

  • Imam Mohammed Ibn Saud Islamic University
  • Imam Mohammed Ibn Saud Islamic University Deanship of Scientific Research

Zitieren

APA

Rejili, M., Hussain, M. S., Haouala, F., Khan, Y., Maqbool, M., & Gupta, G. (2025). Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109097

Vancouver

Rejili M, Hussain MS, Haouala F, Khan Y, Maqbool M, Gupta G. Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.109097

BibTeX
@article{Rejili2025,
  author = {Rejili, Mokhtar and Hussain, Md Sadique and Haouala, Faouzi and Khan, Yumna and Maqbool, Mudasir and Gupta, Gaurav},
  title = {Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation},
  journal = {Bioorganic Chemistry},
  year = {2025},
  doi = {10.1016/j.bioorg.2025.109097}
}
Kostenlos starten →